Last updated on September 2016

Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors

Brief description of study

This is a prospective, international, multi-center, open label, stratified, exploratory phase II study evaluating the efficacy and safety of lenvatinib in patients with advanced/metastatic, neuroendocrine tumors of the pancreas after progression to a previous targeted agent (cohort A) or gastrointestinal tract after progression to somatostatin analogues (cohort B).

Detailed Study Description

Trial to assess the efficacy of Lenvatinib in metastatic neuroendocrine tumor. The primary endpoint of the study is overall response rate (ORR) by RECIST v 1.1 upon central radiologic assessment. Number of patients: 110 patients Estimated duration of subject participation: 24 months

Clinical Study Identifier: NCT02678780

Contact Investigators or Research Sites near you

Start Over

Jaume Capdevila

Hospital de Donostia
Donostia, Spain
  Connect »